Core Insights - Australian researchers have developed a phage therapy composed of five types of bacteriophages to combat a super-resistant bacteria, providing a new precision medicine approach against antibiotic-resistant infections [1][2] Group 1: Phage Therapy Development - The therapy, named Entelli-02, targets the Enterobacter cloacae complex, a group of super-resistant bacteria that have shown resistance to multiple last-line antibiotics, resulting in over 200,000 global deaths in 2019 [1] - The research team initially used three types of bacteriophages but iteratively designed the therapy by genetically modifying and expanding the host range, ultimately identifying two additional phages that enhanced treatment efficacy [1] - The final formulation of Entelli-02 includes five bacteriophages, which can reduce bacterial load in infected mice by over 99% [1] Group 2: Clinical Application and Future Trials - The phage composite has been produced locally in Monash according to therapeutic standards and is currently available for use in hospitals under the "compassionate use" principle, which allows for the use of investigational drugs after existing treatments have failed [2] - The use of "compassionate use" will lay the groundwork for future clinical trials of the phage composite therapy [2]